meta|Evidence - COVID-19

Living meta-analysis and evidence synthesis of therapies for COVID19

tutorial video
En     Fr

Our approach
   

Interactive explorer of NMA results

5CODEX (Tomazini), 2020 CAPE-COVID, 2020 Steroids-SARI, 2020 DEXA-COVID19, 2020 Jamaati, 20211CAP-China (Wang et al.), 202011Li, 2020 Rasheed, 2020 O’Donnell, 2021 Pouladzadeh, 2021 PlasmAr, 2020 AlQahtani, 2020 CAPSID, 2021 REMAP-CAP (plasma), 2021 Sekine (PLACOVID), 2021 RECOVER, 2021 CP-COVID-19, 20211COV-BARRIER (critically ill), 20224Rahmani, 2020 Darazam (COVIFERON Interferon beta-1a), 2021 Darazam (COVIFERON Interferon beta-1b), 2021 Kalil (ACTT-3), 20217CORIMUNO-TOCI-1 (Group 1), 2020 REMAP-CAP (tocilizumab), 2021 Veiga, 2021 COVACTA (Rosas), 2020 Talaschian, 2021 CORIMUNO-TOCI-ICU (Group 2), 2020 Rosas (REMDACTA), 20212Lescure (Sarilumab 400mg), 2021 Lescure (Sarilumab 200mg), 2021baricitinib vs. control 0.54 [0.28; 1.03]0.54 [0.28;1.03]baricitinib vs. control 0.54 [0.28; 1.03]baricitinib vs. convalescent plasma treatment 0.60 [0.30; 1.19]0.60 [0.30;1.19]baricitinib vs. convalescent plasma treatment 0.60 [0.30; 1.19]baricitinib vs. corticosteroids 0.61 [0.29; 1.27]0.61 [0.29;1.27]baricitinib vs. corticosteroids 0.61 [0.29; 1.27]baricitinib vs. interferon 0.89 [0.34; 2.32]0.89 [0.34;2.32]baricitinib vs. interferon 0.89 [0.34; 2.32]baricitinib vs. remdesivir 0.49 [0.17; 1.44]0.49 [0.17;1.44]baricitinib vs. remdesivir 0.49 [0.17; 1.44]baricitinib vs. sarilumab 0.49 [0.19; 1.28]0.49 [0.19;1.28]baricitinib vs. sarilumab 0.49 [0.19; 1.28]baricitinib vs. tocilizumab 0.58 [0.29; 1.16]0.58 [0.29;1.16]baricitinib vs. tocilizumab 0.58 [0.29; 1.16]control vs. baricitinib 1.85 [0.97; 3.53]1.85 [0.97;3.53]control vs. baricitinib 1.85 [0.97; 3.53]control vs. convalescent plasma treatment 1.11 [0.86; 1.42]1.11 [0.86;1.42]control vs. convalescent plasma treatment 1.11 [0.86; 1.42]control vs. corticosteroids 1.13 [0.80; 1.60]1.13 [0.80;1.60]control vs. corticosteroids 1.13 [0.80; 1.60]control vs. interferon 1.65 [0.82; 3.35]1.65 [0.82;3.35]control vs. interferon 1.65 [0.82; 3.35]control vs. remdesivir 0.91 [0.38; 2.15]0.91 [0.38;2.15]control vs. remdesivir 0.91 [0.38; 2.15]control vs. sarilumab 0.91 [0.45; 1.84]0.91 [0.45;1.84]control vs. sarilumab 0.91 [0.45; 1.84]control vs. tocilizumab 1.08 [0.83; 1.39]1.08 [0.83;1.39]control vs. tocilizumab 1.08 [0.83; 1.39]convalescent plasma treatment vs. baricitinib 1.67 [0.84; 3.34]1.67 [0.84;3.34]convalescent plasma treatment vs. baricitinib 1.67 [0.84; 3.34]convalescent plasma treatment vs. control 0.90 [0.70; 1.16]0.90 [0.70;1.16]convalescent plasma treatment vs. control 0.90 [0.70; 1.16]convalescent plasma treatment vs. corticosteroids 1.02 [0.67; 1.57]1.02 [0.67;1.57]convalescent plasma treatment vs. corticosteroids 1.02 [0.67; 1.57]convalescent plasma treatment vs. interferon 1.49 [0.71; 3.16]1.49 [0.71;3.16]convalescent plasma treatment vs. interferon 1.49 [0.71; 3.16]convalescent plasma treatment vs. remdesivir 0.82 [0.34; 2.01]0.82 [0.34;2.01]convalescent plasma treatment vs. remdesivir 0.82 [0.34; 2.01]convalescent plasma treatment vs. sarilumab 0.83 [0.39; 1.74]0.83 [0.39;1.74]convalescent plasma treatment vs. sarilumab 0.83 [0.39; 1.74]convalescent plasma treatment vs. tocilizumab 0.97 [0.68; 1.39]0.97 [0.68;1.39]convalescent plasma treatment vs. tocilizumab 0.97 [0.68; 1.39]corticosteroids vs. baricitinib 1.64 [0.79; 3.41]1.64 [0.79;3.41]corticosteroids vs. baricitinib 1.64 [0.79; 3.41]corticosteroids vs. control 0.88 [0.62; 1.25]0.88 [0.62;1.25]corticosteroids vs. control 0.88 [0.62; 1.25]corticosteroids vs. convalescent plasma treatment 0.98 [0.64; 1.50]0.98 [0.64;1.50]corticosteroids vs. convalescent plasma treatment 0.98 [0.64; 1.50]corticosteroids vs. interferon 1.46 [0.67; 3.21]1.46 [0.67;3.21]corticosteroids vs. interferon 1.46 [0.67; 3.21]corticosteroids vs. remdesivir 0.80 [0.32; 2.03]0.80 [0.32;2.03]corticosteroids vs. remdesivir 0.80 [0.32; 2.03]corticosteroids vs. sarilumab 0.81 [0.37; 1.77]0.81 [0.37;1.77]corticosteroids vs. sarilumab 0.81 [0.37; 1.77]corticosteroids vs. tocilizumab 0.95 [0.62; 1.46]0.95 [0.62;1.46]corticosteroids vs. tocilizumab 0.95 [0.62; 1.46]interferon vs. baricitinib 1.12 [0.43; 2.91]1.12 [0.43;2.91]interferon vs. baricitinib 1.12 [0.43; 2.91]interferon vs. control 0.60 [0.30; 1.22]0.60 [0.30;1.22]interferon vs. control 0.60 [0.30; 1.22]interferon vs. convalescent plasma treatment 0.67 [0.32; 1.41]0.67 [0.32;1.41]interferon vs. convalescent plasma treatment 0.67 [0.32; 1.41]interferon vs. corticosteroids 0.68 [0.31; 1.50]0.68 [0.31;1.50]interferon vs. corticosteroids 0.68 [0.31; 1.50]interferon vs. remdesivir 0.55 [0.18; 1.67]0.55 [0.18;1.67]interferon vs. remdesivir 0.55 [0.18; 1.67]interferon vs. sarilumab 0.55 [0.20; 1.49]0.55 [0.20;1.49]interferon vs. sarilumab 0.55 [0.20; 1.49]interferon vs. tocilizumab 0.65 [0.31; 1.38]0.65 [0.31;1.38]interferon vs. tocilizumab 0.65 [0.31; 1.38]remdesivir vs. baricitinib 2.04 [0.69; 5.97]2.04 [0.69;5.97]remdesivir vs. baricitinib 2.04 [0.69; 5.97]remdesivir vs. control 1.10 [0.47; 2.60]1.10 [0.47;2.60]remdesivir vs. control 1.10 [0.47; 2.60]remdesivir vs. convalescent plasma treatment 1.22 [0.50; 2.98]1.22 [0.50;2.98]remdesivir vs. convalescent plasma treatment 1.22 [0.50; 2.98]remdesivir vs. corticosteroids 1.24 [0.49; 3.15]1.24 [0.49;3.15]remdesivir vs. corticosteroids 1.24 [0.49; 3.15]remdesivir vs. interferon 1.82 [0.60; 5.54]1.82 [0.60;5.54]remdesivir vs. interferon 1.82 [0.60; 5.54]remdesivir vs. sarilumab 1.01 [0.33; 3.05]1.01 [0.33;3.05]remdesivir vs. sarilumab 1.01 [0.33; 3.05]remdesivir vs. tocilizumab 1.18 [0.48; 2.90]1.18 [0.48;2.90]remdesivir vs. tocilizumab 1.18 [0.48; 2.90]sarilumab vs. baricitinib 2.03 [0.78; 5.25]2.03 [0.78;5.25]sarilumab vs. baricitinib 2.03 [0.78; 5.25]sarilumab vs. control 1.09 [0.54; 2.20]1.09 [0.54;2.20]sarilumab vs. control 1.09 [0.54; 2.20]sarilumab vs. convalescent plasma treatment 1.21 [0.58; 2.55]1.21 [0.58;2.55]sarilumab vs. convalescent plasma treatment 1.21 [0.58; 2.55]sarilumab vs. corticosteroids 1.24 [0.57; 2.70]1.24 [0.57;2.70]sarilumab vs. corticosteroids 1.24 [0.57; 2.70]sarilumab vs. interferon 1.81 [0.67; 4.89]1.81 [0.67;4.89]sarilumab vs. interferon 1.81 [0.67; 4.89]sarilumab vs. remdesivir 0.99 [0.33; 3.01]0.99 [0.33;3.01]sarilumab vs. remdesivir 0.99 [0.33; 3.01]sarilumab vs. tocilizumab 1.18 [0.56; 2.48]1.18 [0.56;2.48]sarilumab vs. tocilizumab 1.18 [0.56; 2.48]tocilizumab vs. baricitinib 1.72 [0.86; 3.44]1.72 [0.86;3.44]tocilizumab vs. baricitinib 1.72 [0.86; 3.44]tocilizumab vs. control 0.93 [0.72; 1.20]0.93 [0.72;1.20]tocilizumab vs. control 0.93 [0.72; 1.20]tocilizumab vs. convalescent plasma treatment 1.03 [0.72; 1.47]1.03 [0.72;1.47]tocilizumab vs. convalescent plasma treatment 1.03 [0.72; 1.47]tocilizumab vs. corticosteroids 1.05 [0.68; 1.62]1.05 [0.68;1.62]tocilizumab vs. corticosteroids 1.05 [0.68; 1.62]tocilizumab vs. interferon 1.54 [0.73; 3.26]1.54 [0.73;3.26]tocilizumab vs. interferon 1.54 [0.73; 3.26]tocilizumab vs. remdesivir 0.84 [0.34; 2.07]0.84 [0.34;2.07]tocilizumab vs. remdesivir 0.84 [0.34; 2.07]tocilizumab vs. sarilumab 0.85 [0.40; 1.79]0.85 [0.40;1.79]tocilizumab vs. sarilumab 0.85 [0.40; 1.79]Risk of bias: - high: 0.0 % - some concerns: 60.0 % - low: 40.0 % - NA: 0.0 %corticosteroidsRisk of bias: - high: 0.0 % - some concerns: 0.0 % - low: 100.0 % - NA: 0.0 %remdesivirRisk of bias: - high: 0.0 % - some concerns: 63.6 % - low: 36.4 % - NA: 0.0 %convalescent plasma treatmentRisk of bias: - high: 0.0 % - some concerns: 0.0 % - low: 100.0 % - NA: 0.0 %baricitinibRisk of bias: - high: NaN - some concerns: NaN - low: NaN - NA: NaNtofacitinibRisk of bias: - high: NaN - some concerns: NaN - low: NaN - NA: NaNcasirivimab/imdevimab (Ronapreve)Risk of bias: - high: 0.0 % - some concerns: 100.0 % - low: 0.0 % - NA: 0.0 %interferonRisk of bias: - high: 0.0 % - some concerns: 100.0 % - low: 0.0 % - NA: 0.0 %tocilizumab Risk of bias: - high: 0.0 % - some concerns: 100.0 % - low: 0.0 % - NA: 0.0 %sarilumabRisk of bias: - high: NaN - some concerns: NaN - low: NaN - NA: NaNcontroldirect evidencenetwork meta-analysis ROB:highsome concernslowNA

Click on treatment name to display related network evidence

T vs. C corticosteroidsremdesivirconvalescent plasma treatmentbaricitinibtofacitinibcasirivimab/imdevimab (Ronapreve)interferontocilizumab sarilumabcontrol
corticosteroids---0.80
0.32; 2.03		0.98
0.64; 1.50		1.64
0.79; 3.41		NANA1.46
0.67; 3.21		0.95
0.62; 1.46		0.81
0.37; 1.77		0.88
0.62; 1.25
remdesivir1.24
0.49; 3.15		---1.22
0.50; 2.98		2.04
0.69; 5.97		NANA1.82
0.60; 5.54		1.18
0.48; 2.90		1.01
0.33; 3.05		1.10
0.47; 2.60
convalescent plasma treatment1.02
0.67; 1.57		0.82
0.34; 2.01		---1.67
0.84; 3.34		NANA1.49
0.71; 3.16		0.97
0.68; 1.39		0.83
0.39; 1.74		0.90
0.70; 1.16
baricitinib0.61
0.29; 1.27		0.49
0.17; 1.44		0.60
0.30; 1.19		---NANA0.89
0.34; 2.32		0.58
0.29; 1.16		0.49
0.19; 1.28		0.54
0.28; 1.03
tofacitinibNANANANA---NANANANANA
casirivimab/imdevimab (Ronapreve)NANANANANA---NANANANA
interferon0.68
0.31; 1.50		0.55
0.18; 1.67		0.67
0.32; 1.41		1.12
0.43; 2.91		NANA---0.65
0.31; 1.38		0.55
0.20; 1.49		0.60
0.30; 1.22
tocilizumab 1.05
0.68; 1.62		0.84
0.34; 2.07		1.03
0.72; 1.47		1.72
0.86; 3.44		NANA1.54
0.73; 3.26		---0.85
0.40; 1.79		0.93
0.72; 1.20
sarilumab1.24
0.57; 2.70		0.99
0.33; 3.01		1.21
0.58; 2.55		2.03
0.78; 5.25		NANA1.81
0.67; 4.89		1.18
0.56; 2.48		---1.09
0.54; 2.20
control1.13
0.80; 1.60		0.91
0.38; 2.15		1.11
0.86; 1.42		1.85
0.97; 3.53		NANA1.65
0.82; 3.35		1.08
0.83; 1.39		0.91
0.45; 1.84		---

This project is supported by a grant of the French Ministry of Health (Hospital Clinical Research Program, PHRC-N) and self-funded by Hospices Civils de Lyon, CNRS UMR5558 LBBE University Lyon-1.

   

- About - Our approach - Credits Made with in Lyon - Contact us - Privacy policy - Licence Creative Commons